ELAN vs. ZTS: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ELAN and ZTS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | ELAN | ZTS |
|---|---|---|
| Company Name | Elanco Animal Health Incorporated | Zoetis Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Pharmaceuticals | Pharmaceuticals |
| Market Capitalization | 8.67 billion USD | 69.47 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | September 20, 2018 | February 1, 2013 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of ELAN and ZTS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | ELAN | ZTS |
|---|---|---|
| 5-Day Price Return | -3.00% | 2.42% |
| 13-Week Price Return | 32.07% | -4.38% |
| 26-Week Price Return | 49.74% | -4.95% |
| 52-Week Price Return | 17.81% | -15.03% |
| Month-to-Date Return | 27.63% | 7.52% |
| Year-to-Date Return | 44.18% | -3.79% |
| 10-Day Avg. Volume | 7.06M | 2.89M |
| 3-Month Avg. Volume | 5.85M | 3.14M |
| 3-Month Volatility | 44.59% | 22.66% |
| Beta | 1.64 | 0.92 |
Profitability
Return on Equity (TTM)
ELAN
6.74%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
ELAN’s Return on Equity of 6.74% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
ZTS
53.21%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
ZTS’s Return on Equity of 53.21% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
ELAN
9.68%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
ELAN’s Net Profit Margin of 9.68% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.
ZTS
27.83%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
A Net Profit Margin of 27.83% places ZTS in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
ELAN
16.21%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
ELAN’s Operating Profit Margin of 16.21% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
ZTS
35.35%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
An Operating Profit Margin of 35.35% places ZTS in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | ELAN | ZTS |
|---|---|---|
| Return on Equity (TTM) | 6.74% | 53.21% |
| Return on Assets (TTM) | 3.30% | 18.27% |
| Net Profit Margin (TTM) | 9.68% | 27.83% |
| Operating Profit Margin (TTM) | 16.21% | 35.35% |
| Gross Profit Margin (TTM) | 54.73% | 71.50% |
Financial Strength
Current Ratio (MRQ)
ELAN
2.60
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
ELAN’s Current Ratio of 2.60 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
ZTS
1.76
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
ZTS’s Current Ratio of 1.76 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
ELAN
0.62
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
ELAN’s Debt-to-Equity Ratio of 0.62 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
ZTS
1.32
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
ZTS’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 1.32. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
ELAN
3.08
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
ELAN’s Interest Coverage Ratio of 3.08 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
ZTS
15.44
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
ZTS’s Interest Coverage Ratio of 15.44 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | ELAN | ZTS |
|---|---|---|
| Current Ratio (MRQ) | 2.60 | 1.76 |
| Quick Ratio (MRQ) | 1.18 | 1.04 |
| Debt-to-Equity Ratio (MRQ) | 0.62 | 1.32 |
| Interest Coverage Ratio (TTM) | 3.08 | 15.44 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
ELAN
0.00%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
ELAN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
ZTS
1.24%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
ZTS’s Dividend Yield of 1.24% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
ELAN
0.00%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
ELAN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
ZTS
32.08%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
ZTS’s Dividend Payout Ratio of 32.08% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | ELAN | ZTS |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 1.24% |
| Dividend Payout Ratio (TTM) | 0.00% | 32.08% |
Valuation
Price-to-Earnings Ratio (TTM)
ELAN
20.02
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
ELAN’s P/E Ratio of 20.02 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
ZTS
25.93
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
ZTS’s P/E Ratio of 25.93 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
ELAN
1.94
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
ELAN’s P/S Ratio of 1.94 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
ZTS
7.22
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
ZTS’s P/S Ratio of 7.22 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
ELAN
1.05
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
ELAN’s P/B Ratio of 1.05 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
ZTS
13.95
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
At 13.95, ZTS’s P/B Ratio is at an extreme premium to the Pharmaceuticals industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | ELAN | ZTS |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 20.02 | 25.93 |
| Price-to-Sales Ratio (TTM) | 1.94 | 7.22 |
| Price-to-Book Ratio (MRQ) | 1.05 | 13.95 |
| Price-to-Free Cash Flow Ratio (TTM) | 20.88 | 30.52 |